Morgan Stanley’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $101M | Buy |
6,998,884
+1,519,195
| +28% | +$21.8M | 0.01% | 1431 |
|
|
2025
Q4 | $78M | Buy |
5,479,689
+2,281,019
| +71% | +$22.4M | ﹤0.01% | 1672 |
|
|
2025
Q3 | $25.2M | Sell |
3,198,670
-1,093,692
| -25% | -$7.78M | ﹤0.01% | 2671 |
|
|
2025
Q2 | $24.6M | Buy |
4,292,362
+1,864,228
| +77% | +$12M | ﹤0.01% | 2595 |
|
|
2025
Q1 | $19.8M | Buy |
2,428,134
+306,466
| +14% | +$2.84M | ﹤0.01% | 2698 |
|
|
2024
Q4 | $20M | Sell |
2,121,668
-2,093,663
| -50% | -$21.8M | ﹤0.01% | 2756 |
|
|
2024
Q3 | $45M | Sell |
4,215,331
-777,396
| -16% | -$8.47M | ﹤0.01% | 1926 |
|
|
2024
Q2 | $49.5M | Sell |
4,992,727
-4,712,121
| -49% | -$48.4M | ﹤0.01% | 1769 |
|
|
2024
Q1 | $114M | Sell |
9,704,848
-16,950,946
| -64% | -$217M | 0.01% | 1091 |
|
|
2023
Q4 | $378M | Buy |
26,655,794
+15,907,102
| +148% | +$181M | 0.02% | 797 |
|
|
2023
Q3 | $131M | Sell |
10,748,692
-2,312,116
| -18% | -$29.8M | 0.01% | 904 |
|
|
2023
Q2 | $164M | Sell |
13,060,808
-3,440,101
| -21% | -$40.8M | 0.02% | 800 |
|
|
2023
Q1 | $183M | Sell |
16,500,909
-1,338,445
| -8% | -$16.5M | 0.02% | 733 |
|
|
2022
Q4 | $218M | Buy |
17,839,354
+655,841
| +4% | +$7.38M | 0.02% | 651 |
|
|
2022
Q3 | $179M | Sell |
17,183,513
-1,130,067
| -6% | -$12.6M | 0.02% | 615 |
|
|
2022
Q2 | $197M | Buy |
18,313,580
+1,092,228
| +6% | +$8.99M | 0.03% | 593 |
|
|
2022
Q1 | $163M | Buy |
17,221,352
+3,580,927
| +26% | +$33.6M | 0.02% | 606 |
|
|
2021
Q4 | $158M | Buy |
13,640,425
+1,952,036
| +17% | +$21.8M | 0.02% | 656 |
|
|
2021
Q3 | $112M | Buy |
11,688,389
+28,607
| +0.2% | +$293K | 0.02% | 788 |
|
|
2021
Q2 | $112M | Buy |
11,659,782
+1,693,217
| +17% | +$16.5M | 0.01% | 791 |
|
|
2021
Q1 | $98.5M | Sell |
9,966,565
-2,764,292
| -22% | -$42.8M | 0.01% | 769 |
|
|
2020
Q4 | $294M | Buy |
12,730,857
+1,617,072
| +15% | +$33.1M | 0.05% | 359 |
|
|
2020
Q3 | $157M | Buy |
11,113,785
+2,768,405
| +33% | +$40.3M | 0.03% | 454 |
|
|
2020
Q2 | $126M | Sell |
8,345,380
-4,029,570
| -33% | -$49.1M | 0.03% | 474 |
|
|
2020
Q1 | $114M | Buy |
12,374,950
+17,236
| +0.1% | +$164K | 0.03% | 458 |
|
|
2019
Q4 | $120M | Buy |
12,357,714
+2,057,197
| +20% | +$18.8M | 0.03% | 532 |
|
|
2019
Q3 | $82.6M | Buy |
10,300,517
+3,817,799
| +59% | +$41.4M | 0.02% | 627 |
|
|
2019
Q2 | $80.9M | Buy |
6,482,718
+2,543,211
| +65% | +$32.3M | 0.02% | 634 |
|
|
2019
Q1 | $53.6M | Sell |
3,939,507
-1,412,039
| -26% | -$17.2M | 0.02% | 799 |
|
|
2018
Q4 | $51.3M | Buy |
5,351,546
+836,321
| +19% | +$9.19M | 0.02% | 806 |
|
|
2018
Q3 | $54.6M | Sell |
4,515,225
-453,402
| -9% | -$6.34M | 0.01% | 918 |
|
|
2018
Q2 | $77.6M | Buy |
4,968,627
+4,166,756
| +520% | +$63M | 0.02% | 693 |
|
|
2018
Q1 | $12.1M | Sell |
801,871
-3,808,316
| -83% | -$58M | ﹤0.01% | 2158 |
|
|
2017
Q4 | $66.3M | Sell |
4,610,187
-1,382,063
| -23% | -$19M | 0.02% | 768 |
|
|
2017
Q3 | $90.4M | Sell |
5,992,250
-1,256,964
| -17% | -$16.6M | 0.03% | 610 |
|
|
2017
Q2 | $73M | Buy |
7,249,214
+1,120,733
| +18% | +$9.02M | 0.02% | 713 |
|
|
2017
Q1 | $43.7M | Buy |
6,128,481
+3,055,039
| +99% | +$19.3M | 0.01% | 994 |
|
|
2016
Q4 | $15.3M | Buy |
3,073,442
+3,004,716
| +4,372% | +$20.8M | 0.01% | 1798 |
|
|
2016
Q3 | $509K | Buy |
68,726
+10,578
| +18% | +$71.4K | ﹤0.01% | 4513 |
|
|
2016
Q2 | $317K | Buy |
58,148
+37,688
| +184% | +$264K | ﹤0.01% | 4697 |
|
|
2016
Q1 | $173K | Sell |
20,460
-11,677
| -36% | -$82.7K | ﹤0.01% | 5061 |
|
|
2015
Q4 | $311K | Sell |
32,137
-23,309
| -42% | -$210K | ﹤0.01% | 4851 |
|
|
2015
Q3 | $776K | Buy |
55,446
+8,263
| +18% | +$130K | ﹤0.01% | 4318 |
|
|
2015
Q2 | $668K | Sell |
47,183
-992,352
| -95% | -$11.9M | ﹤0.01% | 4501 |
|
|
2015
Q1 | $11.3M | Buy |
1,039,535
+666,868
| +179% | +$5.88M | ﹤0.01% | 1939 |
|
|
2014
Q4 | $3.1M | Sell |
372,667
-301,372
| -45% | -$2.07M | ﹤0.01% | 3175 |
|
|
2014
Q3 | $4.01M | Buy |
674,039
+328,019
| +95% | +$1.72M | ﹤0.01% | 2823 |
|
|
2014
Q2 | $1.16M | Buy |
346,020
+40,231
| +13% | +$94.4K | ﹤0.01% | 3944 |
|
|
2014
Q1 | $633K | Sell |
305,789
-3,333
| -1% | -$8.33K | ﹤0.01% | 4393 |
|
|
2013
Q4 | $726K | Sell |
309,122
-4,209
| -1% | -$9.24K | ﹤0.01% | 4185 |
|
|
2013
Q3 | $727K | Buy |
313,331
+275,726
| +733% | +$692K | ﹤0.01% | 4061 |
|
|
2013
Q2 | $88K | Buy |
+37,605
| New | +$116K | ﹤0.01% | 5104 |
|
Other funds holding FOLD
VCM
PCM
VPM
GCL
Morgan Stanley's FOLD Position: Q1 2026 in Review
Morgan Stanley increased its Amicus Therapeutics (FOLD) stake by 28% in Q1 2026, buying an estimated $21.8M and bringing the position to 6,998,884 shares worth $101M. The position accounts for 0.01% of the portfolio, ranked #1431.
Morgan Stanley first reported a position in FOLD in Q2 2013 and has held it in 52 quarters since. The position peaked at $378M in Q4 2023. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.
- Morgan Stanley held 6,998,884 shares of Amicus Therapeutics worth $101M as of Q1 2026.
- Morgan Stanley bought 1,519,195 Amicus Therapeutics shares in Q1 2026, an estimated $21.8M.
- Amicus Therapeutics made up 0.01% of Morgan Stanley's portfolio in Q1 2026, its #1431 holding.
- Morgan Stanley first reported a position in Amicus Therapeutics in Q2 2013 and has held it in 52 quarters since.
- Morgan Stanley's Amicus Therapeutics position peaked at $378M in Q4 2023.
- 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.
Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.